Preclinical studies of targeted α therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2

MLA

Barry J. Allen, et al. “Preclinical Studies of Targeted α Therapy for Breast Cancer Using 213Bi-Labelled-Plasminogen Activator Inhibitor Type 2.” British Journal of Cancer, vol. 88, no. 6, Mar. 2003, pp. 944–50. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4a5e64f55f67c042bf2acb4e1053f0f0&authtype=sso&custid=ns315887.

APA

Barry J. Allen, Syed M. Abbas Rizvi, Z. Tian, Yong Li, & Marie Ranson. (2003). Preclinical studies of targeted α therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2. British Journal of Cancer, 88(6), 944–950.

Chicago

Barry J. Allen, Syed M. Abbas Rizvi, Z. Tian, Yong Li, and Marie Ranson. 2003. “Preclinical Studies of Targeted α Therapy for Breast Cancer Using 213Bi-Labelled-Plasminogen Activator Inhibitor Type 2.” British Journal of Cancer 88 (6): 944–50. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4a5e64f55f67c042bf2acb4e1053f0f0&authtype=sso&custid=ns315887.